GIMBHI’s daily mental health update — 10/16/26

🔄 Newport Healthcare brings back former CEO, lays off staff (Behavioral Health Business) — 10/16/26
TL;DR: Nashville-based Newport Healthcare is replacing CEO Brian Setzer with his predecessor, Joe Procopio. It’s also cutting 104 administrative staff and closing more locations as it shifts toward outpatient care.

🤝 Hungry for scale, wary of reimbursement: the behavioral health M&A dilemma (Behavioral Health Business) — 10/15/26
TL;DR: In a BHB survey, more than half of behavioral health providers said they are pursuing or open to acquisitions. Reimbursement uncertainty, including 2027 Medicaid cuts, remains the biggest factor holding deals back.

🍄 Can durable response to psilocybin reshape treatment-resistant depression care? (Psychiatric Times) — 10/16/26
TL;DR: London-based Compass Pathways shared 26-week phase 3 data showing its psilocybin therapy COMP360 delivered lasting symptom relief for some patients with treatment-resistant depression, with no new safety findings.

🧪 Podcast: Using antipsychotic plasma levels to guide schizophrenia treatment (Psychiatric Times) — 10/16/26
TL;DR: UC San Diego psychiatrist Jonathan Meyer says antipsychotic blood levels help spot nonadherence and guide dose increases, and that they tell clinicians more than pharmacogenetic testing.

Previous
Previous

GIMBHI’s daily mental health update — 10/21/26

Next
Next

GIMBHI’s daily mental health update — 10/15/26